Identifying key genes and drug screening for preeclampsia based on gene expression profiles

Area of Science:

• Obstetrics and Gynecology
• Genetics
• Pharmacology

Background:

• Preeclampsia (PE) is a significant global cause of maternal mortality and perinatal complications.
• The precise etiology of PE is not fully understood, but aberrant gene expression is implicated.
• Identifying key genes and therapeutic targets is crucial for effective PE management.

Purpose of the Study:

• To identify key genes and associated biological pathways in preeclampsia (PE).
• To screen for potential therapeutic drugs targeting identified genes for PE treatment.
• To analyze differentially expressed genes (DEGs) in PE using bioinformatics approaches.

Main Methods:

• Acquisition and analysis of the GSE60438 dataset from the Gene Expression Omnibus database.
• Construction of a protein-protein interaction network to identify hub genes.
• Reverse transcription-quantitative PCR for experimental validation of key genes.
• Connectivity Map analysis for drug screening and Gene Set Enrichment Analysis (GSEA).

Main Results:

• Proteasome 26S subunit, non-ATPase 14, prostaglandin E synthase 3, and ubiquinol-cytochrome c reductase core protein 2 were identified as key genes in PE.
• PE pathogenesis is linked to pathways including circadian rhythm, fatty acid metabolism, DNA damage response, and endothelial cell development.
• Furosemide and droperidol emerged as potential therapeutic agents targeting identified hub genes.

Conclusions:

• Novel key genes implicated in the onset of preeclampsia have been identified.
• The study suggests potential drug candidates, furosemide and droperidol, for novel PE therapies.
• Understanding the genetic and molecular underpinnings of PE can pave the way for targeted treatments.